articles details

Darwin Biotech was invited to the 2025 Neurology Center Annual Conference hosted by Beijing TianTan Hospital, Capital Medical University, and entered into a strategic partnership with this hospital.

At the conference, Professor Wang Yilong detailed the development plan of the center, which covers the establishment of a basic and clinical integration research platform, mechanisms to promote multi - center cohort studies on key diseases, and the path of collaborative innovation drug research with enterprises.

The strategic cooperation between Darwin Biotech and Beijing TianTan Hospital heralds a new chapter in China's neuroscience development. By focusing on clinical problems, driving innovation, and promoting industrial collaboration, the partnership aims to provide new solutions for patients with rare neurological diseases. The hospital, a national center for neurological medicine, has been a leader in the field since its founding in 1956. The establishment of the "Center for Rare Neurological Diseases Clinical and Translational Research" marks a forward-looking initiative by TianTan Hospital in rare disease research and mechanism building. It also signifies that China's rare neurological disease research has entered a new phase of multi - dimensional collaborative innovation, kicking off the 2.0 era of China's rare neurological disease diagnosis and treatment system construction.

We look forward to the two parties jointly accelerating the implementation of more Chinese solutions on the challenging but significant path of rare neurological diseases, bringing hope to patients in every corner.